JP2005510487A - メラニン凝集ホルモン受容体1としてのピリミジノン類 - Google Patents

メラニン凝集ホルモン受容体1としてのピリミジノン類 Download PDF

Info

Publication number
JP2005510487A
JP2005510487A JP2003536216A JP2003536216A JP2005510487A JP 2005510487 A JP2005510487 A JP 2005510487A JP 2003536216 A JP2003536216 A JP 2003536216A JP 2003536216 A JP2003536216 A JP 2003536216A JP 2005510487 A JP2005510487 A JP 2005510487A
Authority
JP
Japan
Prior art keywords
formula
group
compound
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003536216A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510487A5 (https=
Inventor
カーペンター,アンドリュー,ジェイ.
クーパー,ジョエル,ピー.
ハンドロン,アンソニー,エル.
ハーツォグ,ドナルド,エル.
ハイマン,クリフトン,イー.
グオ,ユ,シー.
スピーク,ジェイソン,ディー.
ウィッティー,デヴィッド,リチャード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of JP2005510487A publication Critical patent/JP2005510487A/ja
Publication of JP2005510487A5 publication Critical patent/JP2005510487A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/91Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/10Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D257/12Six-membered rings having four nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
JP2003536216A 2001-10-15 2002-10-15 メラニン凝集ホルモン受容体1としてのピリミジノン類 Pending JP2005510487A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124627.1A GB0124627D0 (en) 2001-10-15 2001-10-15 Novel compounds
PCT/US2002/032739 WO2003033476A1 (en) 2001-10-15 2002-10-15 Pyrimidinones as melanin concentrating hormone receptor 1

Publications (2)

Publication Number Publication Date
JP2005510487A true JP2005510487A (ja) 2005-04-21
JP2005510487A5 JP2005510487A5 (https=) 2006-01-05

Family

ID=9923785

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003536216A Pending JP2005510487A (ja) 2001-10-15 2002-10-15 メラニン凝集ホルモン受容体1としてのピリミジノン類
JP2003536220A Pending JP2005508966A (ja) 2001-10-15 2002-10-15 ヒト11CBy受容体に対する拮抗薬としてのラクタム誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2003536220A Pending JP2005508966A (ja) 2001-10-15 2002-10-15 ヒト11CBy受容体に対する拮抗薬としてのラクタム誘導体

Country Status (21)

Country Link
EP (2) EP1436267B1 (https=)
JP (2) JP2005510487A (https=)
KR (2) KR20040045833A (https=)
CN (2) CN1596247A (https=)
AT (2) ATE349434T1 (https=)
BR (2) BR0213242A (https=)
CA (2) CA2463509A1 (https=)
CO (2) CO5580779A2 (https=)
CZ (2) CZ2004499A3 (https=)
DE (2) DE60218721T2 (https=)
ES (2) ES2279009T3 (https=)
GB (1) GB0124627D0 (https=)
HU (2) HUP0402335A3 (https=)
IL (2) IL160872A0 (https=)
MX (2) MXPA04003532A (https=)
NO (2) NO20041504L (https=)
NZ (1) NZ531911A (https=)
PL (2) PL370587A1 (https=)
RU (1) RU2004110053A (https=)
WO (2) WO2003033480A1 (https=)
ZA (2) ZA200402672B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009526792A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアザシクリル置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてのそれらの使用
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
JP2010525077A (ja) * 2007-04-25 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 非塩基性メラニン凝集ホルモン受容体−1アンタゴニスト
JP5000490B2 (ja) * 2005-04-28 2012-08-15 武田薬品工業株式会社 チエノピリミドン化合物
JP2017518309A (ja) * 2014-06-05 2017-07-06 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺虫剤としての二環式化合物

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161717A0 (en) 2001-11-26 2004-09-27 Schering Corp Piperidine-based mch antagonists for treatment of obesity and cns disorders
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060194871A1 (en) * 2003-04-11 2006-08-31 Barvian Kevin K Heterocyclic mchr1 antagoists
CN100418965C (zh) * 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
KR100747042B1 (ko) * 2003-08-19 2007-08-07 솔젠트 (주) 신물질6-메틸-3-펜에틸-3,4-디히드로-1h-큐나졸린-2-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물
US20070078125A1 (en) * 2003-10-23 2007-04-05 Glaxo Group Limited Arylamine mch r1 antagonists
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
UA83416C2 (en) 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
WO2006085692A1 (ja) * 2005-02-14 2006-08-17 Banyu Pharmaceutical Co., Ltd 4(3h)-キナゾリノン誘導体の結晶
WO2007011286A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
KR20080042158A (ko) * 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
KR101384132B1 (ko) * 2005-10-19 2014-04-10 깃세이 야쿠힌 고교 가부시키가이샤 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8329704B2 (en) 2005-12-21 2012-12-11 Janssen Pharmaceutica, N.V. Substituted pyrazinone derivatives for use in MCH-1 mediated diseases
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP1987020B1 (en) * 2006-02-15 2012-10-03 Sanofi Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
WO2007142217A1 (ja) * 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. 1-フェニルピリドン誘導体
MX2008015662A (es) 2006-06-08 2009-01-12 Lilly Co Eli Nuevos receptores antagonistas de la hormona concentradora de melanina (mch).
JP5225269B2 (ja) * 2006-06-08 2013-07-03 イーライ リリー アンド カンパニー 新規なmch受容体アンタゴニスト
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008020799A1 (en) 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
EP2102208B1 (en) 2006-12-05 2014-04-23 Janssen Pharmaceutica NV Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases
CN101558075A (zh) 2006-12-14 2009-10-14 伊莱利利公司 5-[4-(氮杂环丁烷-3-基氧基)-苯基]-2-苯基-5H-噻唑并[5,4-c]吡啶-4-酮衍生物及其作为MCH受体拮抗剂的用途
EP2121654A1 (en) 2007-01-10 2009-11-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
DE102007028925A1 (de) 2007-06-22 2008-12-24 Saltigo Gmbh Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
KR20100044225A (ko) 2007-07-21 2010-04-29 알바니 몰레큘라 리써치, 인크. 5-피리디논 치환된 인다졸
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びppar活性化剤
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 mch 수용체-1 관련 질환에 대한 치료학적 용도
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (https=) 2011-07-01 2018-04-28
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
JP6998937B2 (ja) * 2016-08-12 2022-01-18 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 2-(2-ジアゾニウム-6-置換フェニル)エタノール塩を環化させることによる4-置換2,3-ジヒドロ-1-ベンゾフラン誘導体の製造方法
EP3509588B1 (en) * 2016-09-12 2023-06-07 Integral Health,Inc. Bicyclic compounds useful as gpr120 modulators
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのrasスーパーファミリーと相互作用する化合物
TW201922724A (zh) 2017-09-29 2019-06-16 德商拜耳廠股份有限公司 經取代之3-苯基喹唑啉-4(3h)-酮及其用途
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
CN110563730B (zh) * 2019-07-29 2022-03-25 江苏理工学院 高纯度n10-三氟乙酰蝶酸的制备方法
JP7834721B2 (ja) 2020-08-28 2026-03-24 アルビナス・オペレーションズ・インコーポレイテッド 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
CN113651800B (zh) * 2021-09-07 2022-08-19 山东铂源药业股份有限公司 一种甲磺酸奥希替尼的制备方法
EP4584258A1 (en) 2022-09-07 2025-07-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL137227B2 (en) * 1984-03-28 1986-05-31 Univ Lodzki Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids
IL127296A (en) * 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5000490B2 (ja) * 2005-04-28 2012-08-15 武田薬品工業株式会社 チエノピリミドン化合物
JP2009526792A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアザシクリル置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてのそれらの使用
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
JP2010525077A (ja) * 2007-04-25 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 非塩基性メラニン凝集ホルモン受容体−1アンタゴニスト
JP2017518309A (ja) * 2014-06-05 2017-07-06 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺虫剤としての二環式化合物

Also Published As

Publication number Publication date
ES2279009T3 (es) 2007-08-16
HUP0402335A2 (hu) 2005-02-28
NZ531911A (en) 2004-11-26
CA2463508A1 (en) 2003-04-24
WO2003033480A1 (en) 2003-04-24
BR0213242A (pt) 2004-09-28
ATE356119T1 (de) 2007-03-15
WO2003033476A1 (en) 2003-04-24
DE60217147T2 (de) 2007-10-31
BR0213040A (pt) 2004-10-05
ZA200402814B (en) 2005-04-13
DE60218721D1 (en) 2007-04-19
NO20041504L (no) 2004-05-13
RU2004110053A (ru) 2005-10-20
DE60217147D1 (de) 2007-02-08
CN1571774A (zh) 2005-01-26
CO5580778A2 (es) 2005-11-30
PL370587A1 (en) 2005-05-30
ES2283647T3 (es) 2007-11-01
HUP0402335A3 (en) 2006-02-28
CO5580779A2 (es) 2005-11-30
MXPA04003532A (es) 2004-07-22
JP2005508966A (ja) 2005-04-07
IL161074A0 (en) 2004-08-31
CZ2004499A3 (cs) 2004-08-18
CZ2004498A3 (cs) 2004-07-14
MXPA04003534A (es) 2004-07-22
EP1436267A1 (en) 2004-07-14
KR20040045833A (ko) 2004-06-02
EP1442025B1 (en) 2007-03-07
IL160872A0 (en) 2004-08-31
ATE349434T1 (de) 2007-01-15
DE60218721T2 (de) 2007-11-15
EP1436267B1 (en) 2006-12-27
NO20041503L (no) 2004-05-13
CA2463509A1 (en) 2003-04-24
KR20050043724A (ko) 2005-05-11
CN1596247A (zh) 2005-03-16
HUP0402346A2 (hu) 2005-02-28
ZA200402672B (en) 2005-04-05
EP1442025A1 (en) 2004-08-04
GB0124627D0 (en) 2001-12-05
PL370138A1 (en) 2005-05-16

Similar Documents

Publication Publication Date Title
JP2005510487A (ja) メラニン凝集ホルモン受容体1としてのピリミジノン類
JP7817170B2 (ja) 小分子stingアンタゴニスト
US8329713B2 (en) Fused ring heterocycles as potassium channel modulators
CN105517999B (zh) Ido抑制剂
JP2006522812A (ja) 複素環mchr1アンタゴニスト
JP2023546912A (ja) Mas関連gタンパク質受容体x2のモジュレータ及び関連製品並びにその使用
EA015127B1 (ru) Антагонисты мсн-рецепторов
WO2003091229A1 (en) Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
CN101677554A (zh) 化合物
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
EA015559B1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
AU2004212435A1 (en) Process for preparing pyrrolotriazine kinase inhibitors
US20070219186A1 (en) Pyrazolo[1,5-A]pyrimidine derivatives and methods of use thereof
CN117295734A (zh) 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
US7285557B2 (en) Pyrimidinones as melanin concentrating hormone receptor 1
JP2779219B2 (ja) ベンゾジアゼピン化合物及び該化合物を含有する医薬組成物
WO2011035009A1 (en) Heterocyclic gtp cyclohydrolase 1 inhibitors for the treatment of pain
JP2017525734A (ja) 癌の治療において有用なイソキノリノン誘導体
AU2002335004A1 (en) Pyrimidinones as melanin concentrating hormone receptor 1
JPH04210975A (ja) オキサゾール化合物
JP2024529089A (ja) Stingアンタゴニストとしての小分子ウレア誘導体
JPH0873463A (ja) ベンゾピランカルボキサミド誘導体、その塩及び製法並びに用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20090310

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811